Global Biosimilar Market to Grow Significantly, Predicts Daedal Research in Its Report Available at MarketPublishers.com
06 Dec 2016 • by Natalie Aster
LONDON – The majority of biosimilars are currently in the pipeline since most of the major biologics have expired or are to lose their patent in the near term. For instance, four leading biologics (e.g. Enbel) will expire this year. This will be a major driver the of the overall biosimilar marketplace.
The growing need in the reduction of healthcare expenditure and a rise in the demand for biosimilars in the therapeutic field are some other important driving forces.
Still there is a range of challenges the market has to deal with: regulatory challenges, clinical limitations and obstacles new players face, and more.
Some of noteworthy in this space comprise: the growing use of the single-use technologies, emergence of new entrants in the marketplace, uberization of the healthcare industry, etc.
The market is still in its early stages of the development. It will see exponential growth in the offing. Amgen, Pfizer and Sandoz are amongst leading players globally.
Insightful research report “Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)” elaborated by Daedal Research offers its readers an up-close look at the worldwide biosimilar marketplace. The study starts with a through overview of the overall pharma industry.
It comprises an overview of biologics and biosimilars. The report analyzes the following marketplaces on the basis of value: pharma, biologics and biosimilars. The research study scrutinizes the dynamics of this market.
It further focuses on the competitive environment and profiles major companies (some of them were mentioned above). Future outlook through 2020 is on hand in the research report, as well.
- all-round overview of the marketplace;
- insights into its dynamics;
- coverage of the most important trends;
- focuses on the competitive situation;
- profiles of top players;
- future outlook;
- and more.
For more in-demand studies by our partner, please, visit the Daedal Research page.